Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of Olema Pharmaceuticals Inc (NASDAQ: OLMA) closed at $4.45 in the last session, down -2.63% from day before closing price of $4.57. In other words, the price has decreased by -$2.63 from its previous closing price. On the day, 0.51 million shares were traded. OLMA stock price reached its highest trading level at $4.57 during the session, while it also had its lowest trading level at $4.38.
Ratios:
We take a closer look at OLMA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.22 and its Current Ratio is at 15.22. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on April 02, 2024, initiated with a Buy rating and assigned the stock a target price of $24.
On January 30, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $20.
On July 21, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $21.Oppenheimer initiated its Outperform rating on July 21, 2023, with a $21 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 08 ’25 when Bain Capital Life Sciences Inv bought 300,000 shares for $5.76 per share. The transaction valued at 1,727,370 led to the insider holds 7,800,000 shares of the business.
Graham G. Walmsley sold 700,761 shares of OLMA for $4,730,137 on Dec 17 ’24. The Director now owns 0 shares after completing the transaction at $6.75 per share. On Dec 13 ’24, another insider, Logos Opportunities Fund I LP, who serves as the Affiliate of the company, bought 700,761 shares for $6.75 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OLMA now has a Market Capitalization of 304474752 and an Enterprise Value of -100084360.
Stock Price History:
The Beta on a monthly basis for OLMA is 1.91, which has changed by -0.6137153 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, OLMA has reached a high of $16.62, while it has fallen to a 52-week low of $2.86. The 50-Day Moving Average of the stock is -4.44%, while the 200-Day Moving Average is calculated to be -34.66%.
Shares Statistics:
According to the various share statistics, OLMA traded on average about 889.29K shares per day over the past 3-months and 994870 shares per day over the past 10 days. A total of 68.33M shares are outstanding, with a floating share count of 52.12M. Insiders hold about 23.83% of the company’s shares, while institutions hold 78.40% stake in the company. Shares short for OLMA as of 1749772800 were 6700924 with a Short Ratio of 7.54, compared to 1747267200 on 5903528. Therefore, it implies a Short% of Shares Outstanding of 6700924 and a Short% of Float of 10.780000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of Olema Pharmaceuticals Inc (OLMA) involves the perspectives of 5.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.39 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$1.53 and -$3.03 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$2.23, with 6.0 analysts recommending between -$1.42 and -$3.86.
